Improving how clinics offer long-acting injectable PrEP
Part of Immune system & allergy, Infections clinical trials.
This study looks at the best ways to offer long-acting injectable PrEP (a shot to prevent HIV) in clinics. It involves clinic staff and a review of patient records to improve how this prevention option is delivered.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older if you're a provider or clinic staff member.
- You must work at a participating clinic and be involved in prescribing or supporting PrEP care (for example, as a nurse, doctor, or counselor).
- If you're a patient, you must be 16 or older and have had a PrEP-related clinic visit during the study period at a participating clinic.
- Your medical information will be reviewed in a de-identified way (your name and personal details won't be shared).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at making it easier for young women to get STI and HIV prevention services like PrEP (a daily pill to prevent HIV) when they pick up birth control at a retail pharmacy. It aims to see if offering these services in a pharmacy setting helps women access prevention more easily.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This trial tests a “one-stop” support pathway meant to make it easier for PrEP clinics in Kenya to deliver PrEP care. It involves interviews with people using PrEP services and with healthcare and policy leaders who help run or guide PrEP delivery.
This study looks at ways to improve PrEP (pre-exposure prophylaxis) care by helping clinic staff track and support patients better. It's for healthcare workers, managers, and data staff at certain PrEP clinics.
This study tests a nurse-led program that offers a long-acting injectable medication (cabotegravir) to prevent HIV. The injection is given every two months, and the program aims to make it easier to access this prevention option at your local health center.
This study looks at a long-acting injectable HIV prevention medication (called cabotegravir) to see how well it works in real life. If you are already taking or starting this shot, you may be able to join and help improve HIV prevention care.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.